Exact Mass: 451.1757
Exact Mass Matches: 451.1757
Found 152 metabolites which its exact mass value is equals to given mass value 451.1757
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Doxazosin
Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide
4-Hydroxypropranolol glucuronide
Succinyl-trialanine-4-nitroanilide
(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid
(1S,4R)-1-(beta-D-Glucopyranosyloxy)-4-(6-deoxy-beta-D-gulopyranosyloxy)-2-cyclopentene-1-carboxamide
doxazosin
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3293
Ala Cys Cys Arg
Ala Cys Arg Cys
Ala Arg Cys Cys
Cys Ala Cys Arg
Cys Ala Arg Cys
Cys Cys Ala Arg
Cys Cys Arg Ala
Cys Asp Lys Ser
Cys Asp Ser Lys
Cys Lys Asp Ser
Cys Lys Ser Asp
Cys Gln Thr Thr
Cys Arg Ala Cys
Cys Arg Cys Ala
Cys Arg Ser Ser
Cys Ser Asp Lys
Cys Ser Lys Asp
Cys Ser Arg Ser
Cys Ser Ser Arg
Cys Thr Gln Thr
Cys Thr Thr Gln
Asp Cys Lys Ser
Asp Cys Ser Lys
Asp Phe Gly Asn
Asp Phe Asn Gly
Asp Gly Phe Asn
Asp Gly Asn Phe
Asp Lys Cys Ser
Asp Lys Ser Cys
Asp Asn Phe Gly
Asp Asn Gly Phe
Asp Ser Cys Lys
Asp Ser Lys Cys
Phe Asp Gly Asn
Phe Asp Asn Gly
Phe Gly Asp Asn
Phe Gly Asn Asp
Phe Asn Asp Gly
Phe Asn Gly Asp
Gly Asp Phe Asn
Gly Asp Asn Phe
Gly Phe Asp Asn
Gly Phe Asn Asp
Gly Asn Asp Phe
Gly Asn Phe Asp
Lys Cys Asp Ser
Lys Cys Ser Asp
Lys Asp Cys Ser
Lys Asp Ser Cys
Lys Ser Cys Asp
Lys Ser Asp Cys
Met Asn Ser Thr
Met Asn Thr Ser
Met Gln Ser Ser
Met Ser Asn Thr
Met Ser Gln Ser
Met Ser Ser Gln
Met Ser Thr Asn
Met Thr Asn Ser
Met Thr Ser Asn
Asn Asp Phe Gly
Asn Asp Gly Phe
Asn Phe Asp Gly
Asn Phe Gly Asp
Asn Gly Asp Phe
Asn Gly Phe Asp
Asn Met Ser Thr
Asn Met Thr Ser
Asn Ser Met Thr
Asn Ser Thr Met
Asn Thr Met Ser
Asn Thr Ser Met
Gln Cys Thr Thr
Gln Met Ser Ser
Gln Ser Met Ser
Gln Ser Ser Met
Gln Thr Cys Thr
Gln Thr Thr Cys
Arg Ala Cys Cys
Arg Cys Ala Cys
Arg Cys Cys Ala
Arg Cys Ser Ser
Arg Ser Cys Ser
Arg Ser Ser Cys
Ser Cys Asp Lys
Ser Cys Lys Asp
Ser Cys Arg Ser
Ser Cys Ser Arg
Ser Asp Cys Lys
Ser Asp Lys Cys
Ser Lys Cys Asp
Ser Lys Asp Cys
Ser Met Asn Thr
Ser Met Gln Ser
Ser Met Ser Gln
Ser Met Thr Asn
Ser Asn Met Thr
Ser Asn Thr Met
Ser Gln Met Ser
Ser Gln Ser Met
Ser Arg Cys Ser
Ser Arg Ser Cys
Ser Ser Cys Arg
Ser Ser Met Gln
Ser Ser Gln Met
Ser Ser Arg Cys
Ser Thr Met Asn
Ser Thr Asn Met
Thr Cys Gln Thr
Thr Cys Thr Gln
Thr Met Asn Ser
Thr Met Ser Asn
Thr Asn Met Ser
Thr Asn Ser Met
Thr Gln Cys Thr
Thr Gln Thr Cys
Thr Ser Met Asn
Thr Ser Asn Met
Thr Thr Cys Gln
Thr Thr Gln Cys
4-methylumbelliferyl a-l-idopyranosiduronic acid, cyclohexylammonium salt
Dihydrocodeine bitartrate
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
2-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-D]pyrimidin-5-YL)-ethyl]-benzoylamino}-4-(2H-tetrazol-5-YL)-butyric acid
4-Amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-hydroxybenzamide
(2S)-2-((3-((4-(4-Fluorophenoxy)phenyl)methylcarbamoyl)-4-methoxy-phenyl)methyl)butanoic acid
7-{2-Hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione
PRGL493
PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research[1].